The mission of the Clinical Trials Support Resource is to serve the patients, faculty, and staff of the University of Texas M.D. Anderson Cancer Center by facilitating the approval and performance of clinical research of the highest quality in an ethical and cost-effective fashion. The Clinical Trials Support Resource is supported by the Office of Protocol Research (OPR) staff and is directed by the Associate Vice President for Clinical and Translational Research and an Administrative Director and is divided into four specialized areas: Protocol Approval and Regulatory Affairs, Office of Clinical Research Quality Assurance, Protocol Data Management System, and Research Finance. The Protocol Approval and Regulatory Affairs area supports the protocol approval process for the clinical Research Committee; the Psychosocial, Behavioral, and Health Services Research Committee; and the Surveillance Committee (Institutional Review Board) to ensure that scientific and patient protection issues are adequately addressed and that the protocols are approved at the institutional level before they are submitted to the NCI for approval. The Office of Clinical Research Quality Assurance monitors the quality of research data, serves as resource in improving data management, and provides an institutional mechanism for managing issues related to research deficiencies or problems. This office works closely with the Protocol Approval and Regulatory Affairs staff to ensure that the NCI stipulations are being met and that the requirement for the PRMS designation in protocol accrual is monitored is fulfilled. The Protocol Data Management System staff supports a comprehensive database developed for clinical research personnel at M.D. Anderson Cancer Center. It provides on-line patient registration for all clinical research protocols and is primarily responsible for tracking submission, patient accrual, adverse events, annual reviews, activations, and terminations for all clinical research protocols. It too plays a critical role in the PMRS process. The Research Finance staff is responsible for overseeing the protocol activity in the Clinical Research Unit and utilizing a cost model to prospectively project the cost and charge of protocols. Although each area is involved with special projects, the primary focus of the Clinical Trials Support Resource is to ensure that the principal investigators are in compliance with federal and institutional regulations, to maintain protocol-related information for the institution, to provide protocol management services to investigators, and to refine the financial system surrounding clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S1
Application #
6347269
Study Section
Project Start
2000-08-30
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Scruggs, Stacie; Mama, Scherezade K; Carmack, Cindy L et al. (2018) Randomized Trial of a Lifestyle Physical Activity Intervention for Breast Cancer Survivors: Effects on Transtheoretical Model Variables. Health Promot Pract 19:134-144
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Roman-Gonzalez, Alejandro; Zhou, Shouhao; Ayala-Ramirez, Montserrat et al. (2018) Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268:172-178
Wang, Yugang; Guo, Yusong R; Xing, Dongming et al. (2018) Supramolecular assembly of KAT2A with succinyl-CoA for histone succinylation. Cell Discov 4:47
Okuno, Masayuki; Gourmard, Claire; Mizuno, Takashi et al. (2018) Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival. HPB (Oxford) 20:57-63
Naqvi, Kiran; Cortes, Jorge E; Luthra, Raja et al. (2018) Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107:689-695
Bose, Prithviraj; Nazha, Aziz; Komrokji, Rami S et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132:2100-2103
Loehrer, Andrew P; Chang, David C; Song, Zirui et al. (2018) Health Reform and Utilization of High-Volume Hospitals for Complex Cancer Operations. J Oncol Pract 14:e42-e50

Showing the most recent 10 out of 12418 publications